Ascendis Pharma A/S

Equities

ASND

US04351P1012

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-01 pm EST 5-day change 1st Jan Change
152.5 USD +3.19% Intraday chart for Ascendis Pharma A/S -4.35% +21.06%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer CI
European Equities Traded in the US as American Depositary Receipts Set to End Week Higher in Friday Trading MT
European Equities Traded in US as American Depositary Receipts Move Slightly Higher in Friday Trading MT
Citigroup Raises Price Target on Ascendis Pharma to $182 From $146, Maintains Buy Rating MT
Wedbush Raises Ascendis Pharma's Pt to $225 From $207, Notes Multiple Catalysts Across Pipeline in Q4 2024; Keeps Outperform Rating MT
Ascendis Pharma Q4 Net Loss Narrows, Revenue Rises MT
Transcript : Ascendis Pharma A/S, 2023 Earnings Call, Feb 07, 2024
Earnings Flash (ASND) ASCENDIS PHARMA Posts Q4 Revenue EUR137.7M MT
Ascendis Pharma A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Ascendis Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Cantor Fitzgerald Adjusts Price Target on Ascendis Pharma to $173 From $152, Keeps Overweight Rating MT
European Equities Traded in the US as American Depositary Receipts Make Modest Gains in Thursday Trading MT
Ascendis Pharma A/S Launches 2nd TransCon Product: YORVIPATH Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism CI
European Equities Traded in the US as American Depositary Receipts Move Lower in Tuesday Trading MT
Ascendis Spinning Off Ophthalmology Assets into Eyconis with Venture Firms Backing MT
European Equities Traded in the US as American Depositary Receipts Jump in Wednesday Trading MT
Er-Kim Announces Exclusive Distribution Agreement with Ascendis Pharma A/S to Commercialize 3 Endocrinology Disease Treatments Across Central & Eastern Europe and Turkey CI
Ascendis Pharma Signs Distribution Deals With Vector Pharma, Specialised Therapeutics; Introduces Vision 2030 MT
Wedbush Raises Price Target on Ascendis Pharma to $207 From $202, Maintains Outperform Rating MT
Transcript : Ascendis Pharma A/S Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 09:00 AM
Ascendis Pharma A/S Introduces Vision 2030 CI
Specialised Therapeutics Signs Exclusive Agreement with Ascendis Pharma A/S for Distribution and Commercialisation of Three Endocrinology Therapies in Australia and Select South-East Asia Countries CI
Ascendis Pharma Says Phase 2 TransCon CNP Trial Shows Improved Quality of Life in Children With Achondroplasia MT
Ascendis Pharma A/S Announces New Analyses from Blinded and Ongoing Open-Label Extension Portions of ACcomplisH CI
Wedbush Raises Ascendis Pharma's PT to $202 From $200, Keeps Outperform Rating; Says Among Top Picks for 2024 MT
Chart Ascendis Pharma A/S
More charts
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
140.8 EUR
Average target price
159.7 EUR
Spread / Average Target
+13.41%
Consensus
  1. Stock
  2. Equities
  3. Stock Ascendis Pharma A/S - Nasdaq
  4. News Ascendis Pharma A/S
  5. TD Bank Announcing "Significant Expansion" of Its Global Financial Institutions Group
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW